KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Trial Purpose and Description
This is a research study designed to look at the effects of an investigational chemotherapy drug, KD019, on non small cell lung cancer in comparison to a standard chemotherapy drug, Erlotinib ( Tarceva®).
- 18 Years and older
For Eligibility subjects must have:
• failed one or two previous courses of therapy.
• have no active brain metastasis. Treated non-active brain metastasis are acceptable.
• cannot have received an EGFR inhibitor (Tarceva[erlotinib] or Iressa[gefitinib]) in the past.
• has demonstrated progressive disease.
- Kadmon Corporation, LLC
- November 2012
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale4409252